Minnesota Living with Heart Failure Questionnaire (MLHFQ)

Healthy controls without HF typically score 0–5 on MLHFQ. Stable HF outpatients on optimal therapy average 20–30. Decompensated or newly diagnosed HF patients often score 40–60+. There is no universal 'target' score; the goal is to reduce baseline score by ≥5–10 points or maintain low scores in stable patients.

Baseline assessment is standard at initial HF diagnosis or clinic enrollment. Follow-up frequency varies by clinical context: quarterly (every 3 months) in stable outpatient HF; more frequent (monthly to every 6 weeks) in newly diagnosed, recently hospitalized, or high-risk patients; and at each visit in advanced HF or transplant evaluation cohorts. Minimum interval between assessments to detect meaningful change is 4–6 weeks.

Yes. Several prospective studies show that increasing MLHFQ scores (≥5-point rise from baseline over weeks) precede HF hospitalization by 2–8 weeks, independent of BNP or EF. Rising scores warrant urgent clinical evaluation (assessment for edema, orthopnea, medication adherence, renal function, and diuretic adjustment) to prevent decompensation.

Both are valid, disease-specific HF QoL instruments. MLHFQ is simpler (21 items, single score, 5–8 min) and better for frequent monitoring. KCCQ is more detailed (23 items, 6 subscales, 10 min) and better for capturing domain-specific changes (e.g., symptom vs. emotional burden). Choice depends on clinical workflow: MLHFQ for busy clinics, KCCQ for research or comprehensive assessment.

Moderately. MLHFQ correlates with NYHA class (r ≈ 0.60–0.70) and weakly with EF (r ≈ 0.30–0.40). The modest correlation reflects the reality that perceived symptom burden (QoL) does not perfectly track objective physiology; a patient with EF 20% may report good QoL if well-compensated, while one with EF 40% may report severe limitation if decompensating. MLHFQ and BNP together provide complementary risk stratification.